Orbis Medicines, a cutting-edge biotechnology company specializing in oral macrocycle drug discovery, has successfully raised €90 million in a Series A funding round to advance its innovative pipeline of next-generation oral therapeutics. The financing was led by NEA, with participation from Eli Lilly and Company, Cormorant, the Export and Investment Fund of Denmark, as well as founding investors Novo Holdings and Forbion. This investment will enable Orbis to accelerate the development of its novel drug candidates and expand its proprietary nGen platform.

Orbis Medicines focuses on developing orally available macrocycle drugs, an area of immense potential in modern medicine. Macrocycles, which are often large and complex molecules, have historically been difficult to formulate as oral medications due to poor bioavailability. Orbis is addressing this challenge with its nGen platform, which optimizes macrocycles for oral delivery, potentially offering alternatives to blockbuster biologic drugs that currently require injections or infusions.

The newly secured funding will allow Orbis to advance its lead drug candidates into preclinical and clinical development, while also expanding the capabilities of its nGen platform. The company aims to target disease areas where traditional small molecules and biologics have limitations, such as oncology, immunology, and metabolic disorders. By unlocking the potential of oral macrocycles, Orbis hopes to revolutionize how patients receive treatment, improving both efficacy and accessibility.

Investors and industry leaders see Orbis’ technology as a game-changer in drug discovery. “Orbis Medicines is uniquely positioned to transform macrocycle therapeutics, bridging the gap between biologics and small molecules,” said a representative from NEA. “Their approach has the potential to significantly enhance treatment options for patients with complex diseases.” This sentiment was echoed by Eli Lilly and Company, which has strategically invested in Orbis to explore new avenues in drug development.

The macrocycle drug space is increasingly gaining attention due to its potential to address difficult-to-target proteins that are currently inaccessible to conventional small-molecule drugs. Unlike biologics, which are often expensive and require injection-based administration, oral macrocycles offer a patient-friendly alternative that could increase treatment adherence and improve healthcare outcomes globally.

With this latest funding round, Orbis Medicines is well-positioned to expand its research and development efforts and bring its first wave of macrocycle drug candidates closer to clinical trials. The company is also exploring partnerships with leading pharmaceutical firms to further develop and commercialize its platform. This funding marks a significant step forward in Orbis’ mission to redefine drug discovery and deliver more effective, patient-centric treatments.

As Orbis Medicines continues to push the boundaries of pharmaceutical innovation, the biotech community will be watching closely to see how its oral macrocycle therapeutics can reshape the landscape of modern medicine. With strong investor backing and groundbreaking technology, Orbis is set to become a major player in the next generation of drug development.